Trial Profile
Phase II trial of docetaxel and liposomal doxorubicin (Doxil) chemotherapy combined with enoxaparin in patients with advanced pancreatic cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Doxorubicin liposomal (Primary) ; Enoxaparin sodium (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 08 Apr 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 08 Apr 2009 Planned end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 16 Feb 2007 New trial record.